**Oral Abstract Presentation**

**Time:**  Wednesday, 6\(^{th}\) May 11:30-13:00h

**Chairs:**  Prof. P. Prandoni, Padova, Italy; Prof. P. Reitsma, Leiden, The Netherlands

001  **Coronary microvascular dysfunction due to essential thrombocythemia and polycythemia vera: The missing piece in the puzzle of their increased cardiovascular risk?**  
E. Omenetto, Padua, Italy

002  **Vascular smooth muscle cells are responsible for a prothrombotic phenotype of spontaneously hypertensive rat**  
J. Lagrange, Mainz, Germany

003  **Comparison of risk assessment strategies for not-high-risk patients with acute pulmonary embolism**  
L. Hobohm, Mainz, Germany

004  **Ultrasound-assisted versus conventional catheter-directed thrombolysis for acute iliofemoral deep vein thrombosis**  
A. Stuck, Bern, Switzerland

005  **Local inhibition of fibrinolysis induces chronic thromboembolic pulmonary hypertension in rabbits**  
R. Quarck, Leuven, Belgium

006  **Importance of transforming growth factor-beta for endothelial-to-mesenchymal transition in chronic thromboembolic pulmonary hypertension**  
M. Bochenek, Mainz, Germany
**Poster Session 1 Thrombosis and Hemostasis**

**Time:** Thursday, 7th May 11:30-13:00h

**Chairs:** Prof. B. Laemmle, Mainz, Germany/Bern, Switzerland; Prof. H. ten Cate, Maastricht, The Netherlands

101 **Sensitive D-dimer testing predicts cardiovascular risk and total mortality**  
J. Prochaska, Mainz, Germany

102 **Distribution, genetic and cardiovascular determinants of FVIII:c – Data from the population-based Gutenberg Health Study**  
I. Hermanns, Mainz, Germany

103 **Set up of a biobank of adipose tissue and blood specimens from patients with atherothrombotic disease**  
D. Kareli, Alexandroupolis, Greece

104 **Analysis of inflammatory changes and adipokine expression of different perivascular adipose tissue depots in patients with established coronary atherosclerosis**  
I. Drosos, Alexandroupolis, Greece

105 **Management of severe coronary artery disease in a patient with type Vicenza von Willebrand disease**  
I. Di Pasquale, Padua, Italy

106 **Increased circulating conjugates between platelets and CD14++ CD16-monocytes are associated with enhanced CD11b and thrombospondin-1 surface presentation in patients with stable angina pectoris**  
K. Rosenplaenter, Mainz, Germany

107 **Tissue factor pathway inhibitior (TFPI): An endogenous substrate for factor VII activating protease (FSAP)**  
S. Subramaniam, Mainz, Germany

108 **In-vitro comparison of danaparoid, unfractionated heparin and enoxaparin in preventing thrombus formation on mechanical heart valves**  
A. Kaeberich, Mainz, Germany

109 **Regular medical care versus a telemedicine-based coagulation service for management of oral anticoagulation therapy – Results from the thrombEVAL trial**  
J. Prochaska, Mainz, Germany

110 **Real-world approach to rivaroxaban levels**  
K. Lang, London, United Kingdom

111 **Fibrinogen therapy (Haemocomplettan P) of severe bleeding based on rotational thromboelastometry (Rotem®)**  
S. Maggiolo, Padua, Italy
Poster Session 2 Venous Thromboembolism

Time: Thursday, 7th May 11:30-13:00h

Chairs: Prof. B. Brenner, Haifa, Israel; Prof. G. Meyer, Paris, France

201 Anticoagulation outcomes in pulmonary embolism (PE) with discordant imaging results
C. Yeong, Sydney, Australia

202 Investigation of a new pathophysiological axis for risk stratification of normotensive pulmonary embolism: prognostic impact of copeptin
K. Hellenkamp, Goettingen, Germany

203 Basing risk stratification of normotensive pulmonary embolism on the sPESI as the first step – does it work for all patients? A case report
J. Schwung, Goettingen, Germany

204 Role of venous cava filter insertion in pulmonary embolism
T. Lobo Ferreira, Almada, Portugal

205 A young man with acute pulmonary embolism and very low PESI score. Is he a candidate for home treatment?
A. Janicijevic, Belgrade, Serbia

206 Management and selection of patients with pulmonary embolism in ambulatory care: A retrospective case series
V. Chang, Sydney, Australia

207 A patient with atrial septal defect and pulmonary embolism
L. Baghdasaryan, Yerevan, Armenia

208 Strategies for improved management of thromboembolic diseases: A clinical trial unit supporting translational research
K. Quitzau, Mainz, Germany

209 Strategies for improved acute and long-term management of pulmonary embolism: A clinical trial program
N. Heydenreich, Mainz, Germany

210 Biochemical and genetic biomarkers in sequelae of acute pulmonary embolism (FOCUS BioSeq) study
I. Hermanns, Mainz, Germany
Poster Session 3 Pulmonary Circulation

Time: Saturday, 9\textsuperscript{th} May 11:30-13:00h

Chairs: Prof. M. Humbert, Le Kremlin-Bicêtre, France; Prof. G. Giannakoulas, Thessaloniki, Greece

301 Pulmonary arterial hypertension in Graves’ disease in general hospital, Karawaci, Tangerang, Banten 2012-2013
   A. Kurniawan, Tangerang, Banten, Indonesia

302 Current treatment decisions in chronic thromboembolic pulmonary hypertension
   R. Sadushi-Kolici, Vienna, Austria

303 The predictive role of NT-proBNP and six minute walk test in precapillary pulmonary hypertension
   S. Mouratoglou, Thessaloniki, Greece

304 Comparative analysis of vascular remodeling processes in endarterectomy specimens of patients with CTEPH and in murine venous thrombi
   N. Rosinus, Mainz, Germany

305 Fibrin beta-amino terminus accessibility in dysfibrinogenemias associated with CTEPH
   B. Planquette, Paris, France

306 Vascular endothelial and smooth muscle function and inflammation of pulmonary arteries in a mouse model of deep vein thrombosis
   E. Giokoglu, Mainz, Germany

307 Platelet function in chronic thromboembolic pulmonary hypertension
   R. Sadushi-Kolici, Vienna, Austria

308 Serum amyloid A is elevated in chronic thromboembolic pulmonary hypertension
   R. Sadushi-Kolici, Vienna, Austria

309 Osteopontin – linking acute pulmonary embolism and chronic thromboembolic pulmonary hypertension?
   A. Kaeberich, Mainz, Germany